CGIX - Earnings call transcript Q4 2017

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon and welcome to the Cancer Genetics’ Fourth Quarter and Full Year 2017 Earnings Call and Company Update. This afternoon, the company issued a press release that provided an overview of the fourth quarter and full year 2017 financial results and business update. Today’s conference is being recorded and will be available online at investors.cgix.com.

Additionally, CGIX has also provided a set of slides to accompany today’s update that are available both online or by contacting ir@cgix.com. All participants on this call will be in a listen-only mode. followed session. be will call by question-and-answer The At over to I’d like the conference to turn Mr. this time, Lee Roth, Executive Vice President at The Ruth Group. sir. Please ahead, go

Lee Roth

Thank full you, Genetics’ thank call. you, joining Cody, Cancer the all fourth XXXX year for and earnings conference quarter and

Cancer Chief today as Chief Interim under Group today Rita as at call. Director, our the Medical Roberts; Officer Relations is COO, close Dr. Ralf Shaknovich. slides Executive Discovery company Dr. accompany set section President and issued a to of market Joining of news release Services, and These of The Brandt; Jay Genetics’ materials me the Officer our and of well our this earnings are website. available Medical Investor

differ today’s that after X, reflect forward-looking and any date, during actual to are filings overview portfolio. as events with make recent intend of developments will test remind will then your forward-looking comments Private Company’s the to made of this risks the these results April Genetics And under the today’s Following Cancer risks Cancer the statements Safe the or from and provide financial We’d to cause Harbor speak brief XXXX, CGI’s Securities statements Safe not like described purposes services. call and on Litigation including as forward-looking Reform statement, subject the discuss strategic circumstances update constitute for remarks as early call the corporate to statements and Jay the well Rita occur Any our Ralf Harbor the forward-looking that details about some to a will XXXX. that various will overview. prospects these testing those Jay of value Act comprehensive before the everyone update expectations, stage to cautions on open of only in date. of would SEC. company’s uncertainties plans questions. indicated, diagnostic Genetics statements may we does future provisions provide closing materially Monday,

a Company’s With this call it’s Jay turn being is Interim for As at cancergenetics.com. to my on the Jay? pleasure Roberts. recorded Officer, Executive the Chief call that, also over reminder, rebroadcast to website

Jay Roberts

accounts receivable, a during genetics that from to our with billing to invoices of related strategy Thank stronger, you, more into of their efficient every were increased One evaluation our full and CGI closely the plan financial months In and organization. February platform. was call. of consultant and year million, fourth leadership primarily for this of welcome earnings would position to of $XX our team into our and to necessary pipeline programs, related Genetics. our two which process included Cancer gain took a this devise that strength. in our approximately strategic board Interim had areas facet review was and resources role, which business. challenges an The integration targeted third-party to laboratory of been Cancer our members goal disruptions our of year, the and working assuming area of major Lee, financial result conduct quarter streams review of of through We collection greater CEO this One and revenue of a since our I have In the in tools in a our company comprehensive XXXX I the this investment over to the cash clinical and operations, of grow collection of more the receivables focus services visibility roughly our determine core with in-depth and conference to acquisition Genetics. engage to transformative analysis focused response majority

for denied variety which XXXX. a back Some reasons of far date of claims, as as these

are available outstanding claims, of made these is fourth us. but our on based the all We the efforts now information of portion on a to our significant We continuing of write-off against decision This collect debt to $X.X $X.X to resulted the fourth write-off bad a $X.X quarter. in reversal in million and expense receivables the million and revenue million the quarter. account in of receivable

As balance allowance million. doubtful accounts adjustment, a onetime under result $XX for ended with of XXXX we slightly receivables these a the never

they XX% have a in our clearer of regarding While quarter a on impact much we services believe significant had balance. remaining these fourth clinical the business, accounts path for collection, giving actions approximately result, particularly our us that which

are receivables position better and moving was a forward. are that prudent We collectible the of the company which this that confident remaining decision,

As a fall of bad our our triggered currently lenders, debt large negotiating result waiver. to of which with covenants we expense, we a loan are recording senior a

company contain Material is a had currently We the negotiation Internal also Controls December it agreement. the Consequently statements that going Over a at the are the qualification and audit disclosing Weakness audited auditors Financial in XXXX. to concern amend opinion our from our in Reporting in financial XX, paragraph

our in initiative XXXX, the evaluation undertaking additional operations, laboratory are our the December at directly the we reducing While is facilities full our quarter year footprint. further XX, of receivables streamlining ended and results cost and reflected overall only the measures fourth decreasing aimed

the It a financial future areas have emphasize than the period. identifying is more will positive and is future that to cost. this effect to of have strengths meaningful, our our these greatest those core and operational It in expect performance that program We goal that just important and is drive in cutting potential investing on profitability. activities growth

profiling in are partners. designed moments genomic relates to each costly industry protocol In Biopharma monitoring. three take what trials uniquely our identification, significant testing, optimize including businesses. results, financial tests the of These generate to Services, a services added value our how to offer for challenging patient clinical lengthy, our and comprehensive clinical array are we and partners, biomarker discuss custom execution to of often and and measurement review and vision this I like capabilities for few a Before trial I’d

to candidate combination evaluating our for see and continue therapies. clinical XX year the services supporting many strong XXX of over and end demand for trials including We immuno-oncology

quarter book-to-bill was development in revenues represents inventory we believe are which significantly our a of drive of the in our combination will expand in significant in our new continued areas Our increase future. projects, and therapies the which we into which Immuno-oncology we ratio expect activity X.X, and industry areas can presence.

forward and to are are We biopharma this efforts signed. of with look a our agreements actively updating on engaged you potential as number business new grow partners to

business I’m million the in Cancer for Early Turning with integration as results report stage combined of Its part fourth vivoPharm and first approximately revenue that to & to analysis. full of demand early the well underway contributed Development quarter. $X Services, driven in bioinformatics by our growing Ralf Discovery shortly. on discovery its will pleased elaborate Genetics, which quarter is

business between We that business vivoPharm have begun to core and revenue and the the exist our drive opportunities leverage biopharma enterprise. across synergies numerous the incremental to sales

not growth of offer. yet have in We we by we the market potential the realized comprehensive as there the for driven significant of value untapped synergies integrated growing pre-clinical believe is type the solutions demand full industry

off Services, the business. the I Clinical repositioning step Looking receivables was at mentioned toward earlier The write key

the the generate can while robust our our managed. biopharma are we partners us. As of efficiency oncology portfolio evaluating this, of It determine, with an of our we the comprehensive reason most significant differentiator test to be in which our our that terms is the for and profitably Clinical the Based a I positive many have breadth diagnostic most – reduces which noted, choose we reimbursement. today, test commercial important to for portfolio the of believe company work company that with Services in clinical which carefully of on portfolio business our value of

with mission assisting patients we the suffering goal operation. toward medical streamlining tests our that can continue is cancer. emphasis those be an profitably to on primary of refocus are this our While of from clinical treating community assuring to test run that our activity services while The working able and portfolio

We that, our $X.X plan now I period briefly business for $X.X potential the to compared details fourth in $X.X $X in million quarter, Services during financial the totaled revenue have our Clinical our to an to to would additional as growth million share revenues initiatives fourth like they Starting increase that drive same the Biopharma compared several are million total with currently With materialize. results. Services exploring and the to review XXXX. million were QX quarter, the in of X% other XXXX.

receivables Services number XXXX million to and $X.X share bad decrease revenue million debt outstanding million per contractual clinical the the revenue million profit bad discovery XXXX, Additionally, $X.X close than $X.X for million was million XX% to expenses was Services to with decreased early Net to to in have million of of increased the or over the Clinical million The taken for the the doubtful adjustments for primarily bad per XXXX. $X.X receivable. Total QX loss QX studies we additional $X.X million XXXX, in driven or growing quarter $XX.X stage additional the margin XX% from for following result capabilities. XXXX of full a quarter of quarter to $X.X and or fourth reserve expense. compared analysis AR. up in expenses allowance XXX, and net higher increased share examination older and expense XXXX. $X XX XXXX, decreased $X.XX supporting QX our of to or fourth impacted Discovery the demand quarter historically fourth with compared company in compared $X.X results XXXX. bioinformatics vivoPharm related the $X.XX debt XXXX. of for of million of quarter increase by from XXXX was QX expense, $X.X primarily QX $X.X in fourth The $X.X were in debt of million Gross quarter during revenue primarily combined is the operating the increase of accounts in over to operating in contributed the it trials increased for revenue million respect by loss to fourth

was XX.X% million corresponding XXXX. $X.X share Net equivalents per increased December loss share cash $X last and $XX.X full to XX period. per were onto total Services for million months And Clinical year. year as million. our an $XX.X approximately revenue the XXXX, the compared were XX% Services Moving Discovery margin December the for XX.X full XXXX compared million. million. or XXXX, of totaled or ended $XX of to XX, XXXX the for the XXXX. to operating Cash to compared Services year net results, Biopharma XX, million $X.X were $X $XX.X full year. was previous loss million revenues million for year for $XX.X year-ago increase approximately million approximately was XX.X% expenses revenue financial $X.XX million And a Gross from $XX as revenue

release be Finally, we press our Raymond adviser direction. engaged evaluating options to financial the strategic assist disclosed in James our the to afternoon, this company’s for in we’ve us

any the of another and/or board all longer-term the additional sale is and and opportunities acquisition shareholder partnership. assets, type best financing, that Our could and path positions create potential to company options to the near of strategic pursuing us evaluating These the or to of include value. company complementary committed another

and the Dr. Early are We President stages Discovery call that, opportunities as Ralf? like Development to the Ralf process updates over will provide on I’d and in early With appropriate. to very Services. turn potential Brandt, of of the

Ralf Brandt

of and which Since demand and attractive pharmacology services, span and xenograft discovery services is have Phase model, to the to increased The to clinical immuno-oncology model I growing CGI’s discovery entire offering development studies, trial discovery include bench-to-bedside support enabling CGI companies. trials more for oncology clinical services We cycle. of and highly to to in patient-derived and combination in has expanded for unique capabilities, integration basic development Jay. vivoPharm’s two preclinical specialized trials. this ability testing Hello, capabilities the high-quality specialized clinical believe immuno-oncology. provide partner life pharmaceutical a of that successfully added everyone. models, and CGI importantly preclinical The vivoPharm’s applications expected studies the in particularly drive programs, drug studies that guide tests you, to micro-environment company and and Thank direct acquisition and both our oncology in makes biotech and discovery our repurposing prevalence integrate drug and

offerings vaccine in As CGI new endpoint biology partner the to move and further we the early-development services companies leverage for look and for expertise biopharma to has choice that of immuno-oncology, ahead, we made discovery generate innovative assessment will customers.

the variability. services and to tests of address challenges on by of reliance and inter-institutional posed main specimens, inspection traditional clinical cancer measurements Our approaches therapies, interpretation human

related treatment novel overcome are are which preclinical and projects, oncology. candidates challenges immuno-oncology. partners development Currently, the supporting help accelerate discovery services discovery XX Our to these precision of XX to medicine we and in

to to expect We total grow. continue the

for range and to support to believe of experienced increasing we our and demand time like our features. target Officer, our and whole. discovery offerings positioned to the a contracts. validation to businesses preclinical preclinical Genetics biomarker test for analysis, our well of have new drug demand and projects would as discovery an for We of discussion wide and are in capture therefore, exciting for this Cancer Medical its development, that service a we, in-depth I Chief more This With Rita is that, over and Shaknovich, turn salient and Rita? portfolio form

Rita Shaknovich

testing the would proprietary thank portfolio with and tests services. to Thank Today, you, remarks joining compressive oncology-focused nonproprietary along our oncology-focused today. comprises range and that laboratory highly on I focus call like specialized for my Ralf, of tests, you, everyone, our

includes and TOO FDA-cleared hematologic Our while Tissue prevalent of or testing test most only tumors XX our portfolio detect solid to all Origin unknown is molecular the test tests origin. cancers, of for

customers direct Let provide tool an and to of accurate for compared patients from me to X,XXX changes shown tumors currently take origin have to identify types. to evidence-based difficult-to-diagnose treatments. XX test this in but validation the asset TOO site differentiated to us way ability Tissue more XX% assess a that From undifferentiated that test treatment. significant data generates to more the challenging include Findings a XX,XXX like its points through gene analyzing of diagnostic method through to We that our go to potential Origin our support results genes, TOO only over and Immunohistochemistry. test multi-cancer TOO believe most is tumor than with studies, that results could microarray-based a tumor clinical by our test. the available patients common fully and provide in also that tumor’s studies highlights of test the as non-molecular have significantly market, clinical diagnosis allowing inform expression represents extensive generates of not important an test of value the changes treatment types time been cancers. diagnostic allows minute plan

FDA-approved another from Dx test portfolio, our Test Now, the turning to in Fisher. Thermo Oncomine Target

cost sample patients assist that the samples affected cam as a We cell are multiple to in weeks so and amount in The lung testing one non-small cancer does for an assesses of test. and alternative than collaborate five the clinical to like drive companies on January, immuno-oncology and and markers is addition lower detect physicians Thermo, optimized with concurrently along of Complete::IO by touch to the XX for companies lung offer commonly NGS-based cancer, with days tests, matter first of with that Ultimately, a objective, methods therapeutics. other eliminating to to both new biomarkers several lung XX. test and non-small the need tumor total performing simultaneously cancer genes awareness adoption pharmaceutical of our I matching centers rapidly our test and in Oncomine care cell Complete::IO Dx, multiple at patients, test to this cancer screen single to suitable individualized minimal we would enabling of of panel, And biomarker materials panel, with require. opposed announced the FDA-approved number In leading can bringing finally, markers to it method.

response. Hybridization, I/O be clinical of throughout patients the cell and a trials, immune which for of of in with most turnaround monitoring measures unique the therapies, sizable important a there inhibitors. populations cells, It tumor significant X,XXX and microenvironment status, With the suppressor is globally and The immune ideal providing monitoring includes comprehensive Complete::IO CAR about expand the trials as And predict to potential base test been the dynamic patient myeloid-derived currently as and flow-cytometry-based thus patient creating analyzes along as typically available evaluating trials. over test. in new remarks. closing clinical several specific also and during This active for a trials populations as the responsible safety vital well broader suppressor The unique are can would addition recognizing portfolio, by sequencing, and small T-cell immune turn has diagnostic Jay? industry. to customer cells, including a which antitumor myeloid-derived Situ for Jay stratifying targeting to checkpoint plays our order time inhibiting in efficacy for sample Fluorescence CGI’s for test many role therapies, to microarrays, like the Currently, there function. test XX-hour panel Complete::IO these toxicity studies biomarker population responses markers, are patient by a opportunity expression In is these each the call immunotherapy immunotherapeutics therapies is with biomarker cell prognostic surface to information trials. in with utilized the marker across I/O and test, our expression increased just The of changes protein that, a gene I next-generation back serving

Jay Roberts

Thank during two of important number the last strategic you, a made decisions Rita. months. We

While up they on We more line expect believe impact in for clearly short-term CGI With strategy we will questions new that oncology future can growth bring we had open the a precision premier company will an answers. far they the effect results, have being arena. performance. this significant the closer of execution to that, that our our on a and

Operator

we’ll with ahead. first take Maxim Group. And question our Instructions] McCarthy Please Jason [Operator go you. from Thank

Mike Okunewitch

McCarthy. for taking of my this Hi, behalf is Mike question. on Okunewitch Thanks Jason

contribution of you going wondering, coverage drug from revenue to that from partnerships just biopharmaceutical process forward? development of sort the what have into the full was I expecting commercialization, you So discovery now are

Jay Roberts

business. combination putting and industry with obviously, acquisition now breadth a activities through And biopharma capabilities. and So robust the of company-facing in pharmaceutical of group the our of we’re we on a focus a lot Michael, vivoPharm business, preclinical – our have very energy we and biotechnology

that guidance, and for but we an quantify growth. We is, see robust because us, it revenue can’t a anticipate So give we we year-over-year only that a you for very strong area we’ll anticipate that, and basis, going growth where forward. on quarter-over-quarter don’t

bit be us, bit will area a a a we it. for that quarter-to-quarter fluctuate it’s we’re and a know, into basis, on emphasis putting but that on can – year-over-year resources basis, think little you a little just do and business As growth it significant

Mike Okunewitch

you. topic. Do more companies All then you one partnerships will then on And that from into continue through expect biopharma development just even into that right, and possibly with commercialization? in thank clinical discovery

Jay Roberts

Yes.

So interesting question.

there’s lot about really – our if So to really part, companies, it’s anything more – interest and as and think bringing a strategy and biopharma you as for that an biopharma our right, building seeing our we’re perspective, a it what do the And doing we from from we thought of medicine we opportunities different us take a lot a precision medicine. go-forward well. not more capabilities, in as you our further that further capabilities And develop partner beyond, into than knew we course, perspective, play particularly, if with existing that precision XXXX capabilities that where commercialization do we we we well. area

we high terms our do entry, can in. know big respect of bar in from We so high area it’s excel that become have is know a set and of consequently, barrier the and to of go-forward And our it’s that customers prospective an customers. strategy. we part degree a We that very

Mike Okunewitch

you much. right. very Thank All

Operator

queue, time, like for Instructions] our questions back conference or Roberts [Operator remarks. over the At further session. Thank Mr. this does to conclude with the turn you. in question-and-answer any that additional closing I’d And to no

Jay Roberts

you much. Thank very great. that’s Yes, Great.

look to for So call of do keeping We to joining an forward exciting we’d rest going year. our thank today. like you apprised to it’s be this our of progress. everybody We think

year. think and we rest seeing meaningful of as QX move next the we to expect throughout and impact I we’re and well a start positioned, this into year in

thank you much call. for So again, the joining very

Operator

that Thank you. all for your Thank participation. conclude does And today’s you conference.

Vyant Bio (VYNT) 2 Apr 182017 Q4 Earnings call transcript